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Abstract
Estrogen receptor alpha (ERα) is a ligand-activated nuclear receptor that directs proliferation and differentiation in selected
cancer cell types including mammary-derived carcinomas. These master-regulatory functions of ERα require trans-acting
elements such as the pioneer factor FOXA1 to establish a genomic landscape conducive to ERα control. Here, we identify
the H3K4 methyltransferase KMT2C as necessary for hormone-driven ERα activity and breast cancer proliferation. KMT2C
knockdown suppresses estrogen-dependent gene expression and causes H3K4me1 and H3K27ac loss selectively at ERα
enhancers. Correspondingly, KMT2C loss impairs estrogen-driven breast cancer proliferation but has no effect on ER- breast
cells. Whereas KMT2C loss disrupts estrogen-driven proliferation, it conversely promotes tumor outgrowth under hormonedepleted conditions. In accordance, KMT2C is one of the most frequently mutated genes in ER-positive breast cancer with
KMT2C deletion correlating with signiﬁcantly shorter progression-free survival on anti-estrogen therapy. From a therapeutic
standpoint, KMT2C-depleted cells that develop hormone-independence retain their dependence on ERα, displaying ongoing
sensitivity to ERα antagonists. We conclude that KMT2C is a key regulator of ERα activity whose loss uncouples breast
cancer proliferation from hormone abundance.
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Cancer-speciﬁc transcriptional programs are foundational to
the development of oncogenic phenotypes. For example,
oncogenes such as MYC and BRAF drive unique gene
expression signatures that have been shown to be essential
for transformation and cancer maintenance [1–5]. From a
therapeutic vantage, reversal of these transcriptional programs is critical to the efﬁcacy of most forms of targeted
therapy.
Recent large-scale genomic analyses have identiﬁed key
chromatin modiﬁcations permissive of such tissue-speciﬁc
and cancer-speciﬁc transcriptional programs [6, 7]. Among
the most signiﬁcant of these chromatin modiﬁcations is
methylation at histone H3 lysine 4 (H3K4me), generally
marking regions of active and poised transcription. H3K4
histone methyltransferases mono-methylate H3K4, dimethylate H3K4, or tri-methylate H3K4 via their enzymatically active SET domain. Trimethylation (H3K4me3) of
these residues is observed to be more abundant at promoter
regions while monomethylation (H3K4me1) is more abundant at enhancer regions [8].
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Fig. 1 KMT2C is the most frequently mutated H3K4 histone
methyltransferase in breast cancer. a Mutation frequencies of H3K4
histone methyltransferases in breast cancer tissue samples from the
TCGA data set [10] (n = 818). b Percentage of cases with gene

mutations detected in the MSKCC-IMPACT metastatic breast cancer
patient cohort [60] (n = 746). c Diagram of KMT2C domains with the
locations of the identiﬁed TCGA mutations. y-axis corresponds to the
number of cases with indicated mutation (n = 818)

Interestingly, data from several large-scale cancer
sequencing studies have identiﬁed KMT2C (also referred to
as MLL3), which encodes an H3K4 histone methyltransferase, as one of the most commonly mutated genes in
breast cancer with a mutation frequency of approximately
8% [9–11]. KMT2C, which is partially redundant with its
most closely related homolog, KMT2D, is thought to be an
H3K4me1/2 methyltransferase active predominantly at
enhancer regions of the genome [12, 13]. The high prevalence of KMT2C mutation suggests that KMT2C may
have important functions in breast cancer, which is so often
characterized by its dependence upon the transcription
factor, ERα. Here, we investigated the role of KMT2C in
breast cancer pathogenesis and found it to be an essential
ERα coactivator.

mutation in breast cancer pathogenesis, we examined
KMT2C mutation frequency in metastatic tumors. KMT2C
mutations were found in 9.8% of over 700 metastatic breast
tumors analyzed, placing it among the most commonly
mutated genes in breast cancer (Fig. 1b). The majority of
KMT2C mutations are frameshift, truncation or missense
mutations, with a substantial proportion predicted to interfere with expression of the carboxy-terminal SET domain
(Fig. 1c). The mutations appear to occur in all breast cancer
subtypes with a relatively even distribution (Fig S1).
Together this data suggests that KMT2C may act as a breast
cancer tumor suppressor and might be a candidate regulator
of H3K4me in these tumors.

Results

In order to test the function of KMT2C in breast cancer, we
cloned two short hairpins against KMT2C [14] (shKMT2C).
We found that both short hairpins, shKMT2C#1 and
shKMT2C#2, reduce expression of KMT2C by 60–70%
without affecting expression of its most closely related
homologs, KMT2A, B, or D (Fig. S2A). We stably expressed shKMT2C#1 and shKMT2C#2 in a panel of cell lines
representative of the clinical subtypes of breast cancer and
found similar degrees of knockdown across the panel (Fig.

KMT2C is one of the most frequently mutated genes
in breast cancer
Within the H3K4 methyltransferase family, KMT2C is by
far the most commonly mutated member with a frequency
of approximately 8% in TCGA breast cancer samples [10]
(Fig. 1a). To assess the presence and persistence of KMT2C

KMTC2 knockdown reduces cell proliferation of ER+
breast cancer cells
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Fig. 2 KMT2C loss inhibits proliferation of ER+ cells. a–d Breast
cancer cells stably expressing either shRenilla or shKMT2C were
assayed for proliferation using the alamarBlue cell viability assay.
Values correspond to the mean of six experimental replicates ± s.e.m.
All cells are cultured in full serum containing media e. Parental and
MCF7 KMT2C CRISPR cells were assayed for proliferation using the
alamarBlue cell viability assay. Values correspond to the mean of six

experimental replicates ± s.e.m. Data correspond to one representative
assay from a total of two or three independent assays. f–i Indicated
breast cancer cells stably expressing either shRenilla, shKMT2C or
shKMT2D were assayed for proliferation using the alamarBlue cell
viability assay. Values correspond to the mean of six experimental
replicates ± s.e.m.

S2B). All cell lines used underwent next-generation
sequencing and showed no clear deleterious mutation in
KMT2C (Supplementary Table 1). To conﬁrm sufﬁcient
knockdown of KMT2C protein levels, we used MCF7 cells
that have been engineered to express HA at the C-terminal
end of an endogenous KMT2C allele (KMT2C-HA cells).

Expression of shKMT2C #1 and shKMT2C #2 in these
cells resulted in knockdown of KMT2C-HA by immunoblotting (Fig. S2C), while not affecting protein levels of
KMT2A, B or D (Fig. S2D).
We subsequently used the shKMT2C-expressing breast
cancer models to assay the effects of KMT2C loss on cell
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proliferation. KMT2C knockdown resulted in a 40–70%
reduction in proliferation selectively in the three ER+HER2
− cell lines examined, MCF7, T47D and Cama-1 (Fig. 2a).
In contrast to the effects seen in the ER+HER2− cells lines,
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KMT2C knockdown had no effect on the proliferation of
the ER+HER2+ cell line BT474, the ER-HER2+ cell
lines, SKBR3 and HCC1954 and the triple negative cell
lines, MDA-MB-231, MDA-MB-468, MCF10A and
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Fig. 3 KMT2C loss suppresses ERα target gene expression. a
Supervised analysis of the 7938 differentially expressed genes between
shRenilla and shKMT2C (shKMT2C#1 and #2 combined) MCF7
cells. All cells are cultured in full serum containing media. b GSEA
showing 3857 genes downregulated in shKMT2C cells are enriched
among genes downregulated following 5-day estrogen deprivation of
shRenilla cells (≥3-fold). c GSEA of 3857 genes downregulated in
shKMT2C as compared to the Hallmark Estrogen Response Early
Geneset (Broad Institute). d GSEA of 3857 genes downregulated in
shKMT2C as compared the Hallmark Estrogen Response Late Geneset. e mRNA levels; values correspond to the mean of three replicates
± s.e.m. E2, estradiol. f mRNA levels; values correspond to the mean
of three replicates ± s.e.m.; two-tailed Student’s t-test with a desired
FDR = 1% was used to determine statistical signiﬁcance; **P < 0.01,
***P < 0.001, ****P < 0.0001. Data correspond to one representative
assay from a total of two or three independent assays. g Immunoblot;
β-actin used as loading control. h mRNA levels, as measured by qRTPCR, from RNA taken from the mammary glands of 12-week old
virgin females. Values correspond to the mean of three replicates ± s.e.
m. i Representative slides of PR expression in mammary glands from
12-week-old virgin females

HCC1806 (Fig. 1b–d). Similarly, CRISPR/Cas9nickase
mediated knockout of KMT2C suppressed proliferation in
MCF7 cells (Fig. S3, Fig. 1e) but not in MCF10A cells
(data not shown). Given the close homology between
KMT2C and KMT2D, we examined whether loss of
KMT2D would have similar effects on the proliferation of
ER+ breast cancer cell lines. We expressed shKMT2D in a
representative panel of breast cancer cell lines resulting in
approximately 50–70% knockdown of KMT2D mRNA
(Fig. S4). We observed that while the effects of KMT2C
loss on proliferation were speciﬁc to the ER+HER2− cell
lines, loss of KMT2D suppressed the proliferation of all cell
lines tested except MDA-MB-231 (Fig. 2f–i). This suggested that the effects of KMT2C on ER+/HER2− breast
cancer proliferation may be unique and not shared by all
H3K4 methyltransferases, prompting us to further investigate its role in estrogen response.

KMT2C loss suppresses ERα target gene expression
Given the effects of KMT2C loss on estrogen-driven breast
cancer models, we next examined whether and how
KMT2C might be regulating signaling by ERα. We assessed the effect of KMT2C loss on global receptor activity by
evaluating ERα expression, phosphorylation and conformational stability. We found no major changes in the
levels of total ERα in both MCF7 and T47D cells (Fig. S5A
and S6). In addition, we found no changes in phosphorylation of ERα (S118 or S104/S106) or in the HSP90
dependence of ERα after KMT2C knockdown (Fig. S5 and
S6). Given the lack of effects upon ERα expression or
conformation, we next sought to determine whether there
might be changes in aspects of ERα-regulated gene
expression.

K. Gala et al.

To this end, we performed RNA sequencing on control
shRenilla and shKMT2C MCF7 cell lines (Fig. 3a). We
then compared the gene expression changes following
KMT2C knockdown to those following 5-day hormone
deprivation of control shRenilla cells. We found that genes
that were downregulated following KMT2C knockdown
were strongly enriched among genes downregulated following hormone deprivation (Fig. 3b). Additionally, upon
comparing the downregulated genes in the KMT2C
knockdown cells to Hallmark gene sets, we found strong
enrichment speciﬁcally among ERα target gene sets (Fig.
3c, d). In further support, we performed RNA sequencing of
ER+T47D cells following KMT2C knockdown. We again
found genes downregulated by KMT2C loss to be highly
enriched among ERα target gene sets (Fig. S7A–C). We
validated the differential gene expression data using qRTPCR on a panel of ERα target genes whose expression was
stimulated with E2 (Fig. 3e). Expression of all of these
transcripts was reduced by 5–60% following KMT2C
knockdown in MCF7 T47D and Cama-1 cells (Fig. 3f, S7D,
E). To further conﬁrm these ﬁndings, we examined protein
expression of progesterone receptor (PR), a well-established
ERα target, and found it to be decreased by approximately
70% following KMT2C loss (Fig. 3g).
To determine whether Kmt2c might regulate ERα
activity in another context where ligand-activated ERα
regulates cellular proliferation and differentiation, we
examined the role of KMT2C in the murine mammary
gland. We generated mice with ﬂoxed alleles of Kmt2c (Fig.
S8A-C) and crossed them with mice expressing Cre
recombinase under the control of the mammary-speciﬁc
MMTV promoter (Fig. S8D-F). We assayed for several
ERα target genes in both control and Kmt2c knockout
glands. We found reduced expression of multiple ERα
target genes in the Kmt2c knockout mice to levels that were
approximately 40–90% below levels seen in control mice
(Fig. 3h). In addition, we assayed for nuclear expression of
the PR, a known ERα-target gene, by IHC and found signiﬁcant reductions (Fig. 3i). These data conﬁrm that
KMT2C regulates key aspects of the estrogen response
program while not globally controlling ERα expression or
activity.

KMT2C loss suppresses ERα function at enhancer
sites
It has been speculated that H3K4me may help demarcate
regions for ERα binding and activity [15]. Given the known
enzymatic activity of KMT2C in generating H3K4me in
other cell types [16], we hypothesized that KMT2C might
regulate ERα activity by placing these marks at ERα
binding sites. We ﬁrst examined total H3K4me1 and
H3K4me3 levels by immunoblotting and found no change
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following KMT2C loss, implying that KMT2C is not the
sole methyltransferase responsible for these marks in ER+
cells (Fig. 4a). We next examined the pattern of genome-
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wide H3K4me1 and H3K4me3 following KMT2C loss
using ChIP-sequencing. Whereas KMT2C loss had no
meaningful effect upon H3K4me3 across the genome (data
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Fig. 4 KMT2C loss results in site-speciﬁc loss of H3K4me1 and
H3K27ac at ERα enhancers. a Immunoblot; β-actin used for loading
control. b Normalized heatmaps for H3K4me1 occupancy in shRenilla, shKMT2C#1 and #2 cells among the 869 differential sites.
Heatmaps centered at the peak summit. All cells are cultured in full
serum containing media c GSEA of 3857 genes signiﬁcantly downregulated in MCF7 shKMT2C cells (p-val < 0.05) as compared to
ranked genes with a ≥ 25% reduction in H3K4me1 at enhancers in
shKMT2C cells. d qChIP analysis; IgG used as negative control.
Values correspond to mean percentage of input ± s.e.m. of triplicate
qPCR reactions of a single replicate. e qChIP analysis; Two-tailed
Student’s t-test with a desired FDR = 1% was used to determine statistical signiﬁcance; **P < 0.01, ***P < 0.001, ****P < 0.0001. Data
correspond to one representative assay from a total of three independent assays. f Average H3K27ac binding in shRenilla and shKMT2C
MCF7 cells at sites of H3K4me1 loss centered at peaks ± 1kB.
shKMT2C#1 and #2 H3K27ac peaks were averaged to generate the
shKMT2C proﬁle. g List of differentially bound ERα binding partners
in shKMT2C#2 vs. shRenilla MCF7 cells. H/L refers to the ratio of
peptides found in the heavy (shKMT2C) vs the light (shRenilla)
labeled lysates. List was restricted to previously established ERα
binding partners [23]. Assay done in triplicate. Full list found in
Supplementary Table 2

not shown), it appeared to selectively alter H3K4me1 at 869
affected loci, or 1% of the total 84,484 sites of H3K4me1
occupancy in control cells (Fig. 4b, Fig. S9).
To analyze the functional signiﬁcance of these sites of
H3K4me1 loss, we integrated these data with the RNA
sequencing data (Fig. 3a) and found a strong enrichment for
sites with H3K4me1 loss with sites whose nearby genes
showed diminished expression with KMT2C knockdown
(Fig. 4c). To be sure, we also included assessment of
decreased H3K4me1 at promoter regions and found that it
also correlated with decreased gene expression (Fig. S10).
However, the 73 promoter sites that correlated with reduced
gene expression accounted for a small portion of overall
KMT2C-mediated H3K4me1 loss. This is again consistent
with previous studies indicating that H3K4me1 demarcates
activity at enhancers as opposed to promoters. To conﬁrm
these effects upon ERα enhancers, we examined H3K4me1
at known ERα enhancer sites and found decreases in
H3K4me1 from 15% at the PGR enhancer to 80% at the
CA2 enhancer (Fig. 4d), given the prior data that ERα
regulates gene expression through its actions at both promoter and enhancer sites, our integrated H3K4 methylation
and RNA sequencing data points to KMT2C predominantly
altering ERα activity via its effects upon ERα enhancer
sites.
As the H3K4me1 mark is known to demarcate both
regions of active transcription and regions “poised” for
transcription, histone H3 K27 acetylation (H3K27ac) can be
used to more strictly delineate those sites that are actively
engaged in transcription [17]. To determine if KMT2C was
regulating active enhancers, we assayed for H3K27ac at the
AGR3, CA2, and PGR enhancer sites, where we saw loss of
H3K4me1. We found signiﬁcant reduction of H3K27ac at
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these sites (Fig. 4e). We went on to perform H3K27ac
ChIP-sequencing on KMT2C knockdown MCF7 cells and
found that H3K27ac was coordinately reduced at sites of
H3K4me1 loss (Fig. 4f, Fig. S11). These data further
establish a model in which KMT2C is responsible for
depositing H3K4me1 selectively at active ERα enhancers
thereby facilitating a key aspect of the ERα regulon.
H3K4me1 may facilitate enhancer function by promoting
binding of any of a number of components necessary for
site-speciﬁc transcription. It has been speculated that DNAbinding of ERα itself may require H3K4 methylation and/or
pioneer factor binding [15, 18, 19]. To test this hypothesis,
we examined ERα ChIP-sequencing in KMT2C knockdown cells. Unlike the case with H3K4me1/H3K27ac, we
did not observe major loss of ERα binding at sites of
changes in gene expression (Fig. S12A). Not surprisingly,
we did ﬁnd a handful of sites with decreased ERα binding
and concomitant decreases in proximal gene expression
(Fig. S12B). However, the 12 genes accounted for by loss
of ERα binding were only 0.3% of the total gene expression
changes observed. Moreover, we observed no change in
levels of ERα at > 75% of ERα binding sites proximal to
sites we found to have KMT2C dependent H3K4me1 (Fig.
S12A). As such, the data points to KMT2C regulating ERα
enhancer function perhaps via its facilitation of essential
ERα coactivators, but not via recruitment of ERα itself.
In order to nominate potential coactivators involved in
mediating the effects of KMT2C upon on ERα, we performed de novo motif analysis upon a 1kB radius around
sites where H3K4me1 had decreased in shKMT2C cells.
We found that these regions were signiﬁcantly enriched
over randomly selected background sequences for the wellknown ERα pioneer factor, FOXA1 [15] as well as the ERα
coactivator, AP-1 [20] (Fig. S13). While a number of motifs
were considered to be signiﬁcant in this analysis, it is
notable that these two are both known factors necessary for
ERα action. To further screen for potential intermediaries
between KMT2C and ERα activity, we looked for changes
in the ERα interactome. Given the large number of potential
interactions, we sought to restrict this search to interactions
occurring on DNA. To this end, we employed rapid
immunoprecipitation mass spectrometry of endogenous
proteins (RIME) [21, 22] with shKMT2C#2 MCF7 cells
cultured in heavy SILAC media and shRenilla MCF7 cells
cultured in light SILAC media. We compared our list of
peptides differentially bound to ERα with previously published ERα-binding partners [23]. These data revealed only
modest changes with most interactions comparable between
cells (Fig. 4h). However, they did reveal reduced binding of
ERα to MCM4, FOXA1, and TRPS1 by over 1/3 in
shKMT2C cells and no proteins showing enhanced binding
(Fig. 4h, full list Supplemental Table 2). Taken together, the
ﬁndings point to a possible role for KMT2C in regulation of
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Fig. 5 KMT2C loss promotes hormone independent outgrowth. a
Cells were assayed for proliferation in CSS media using the alamarBlue viability assay. Values correspond to the mean of six experimental replicates ± s.e.m. Data correspond to one representative assay
from a total of two independent assays. b Supervised analysis of the
8622 differentially expressed genes between shKMT2C#2 cells in CSS
media for 5 days and shKMT2C-R. CSS, charcoal stripped media. c
Supervised analysis of the 9398 differentially expressed genes between
shRenilla cells in CSS media for 5 days and shKMT2C-R. d GSEA of
4347 genes signiﬁcantly downregulated in b as compared to the
Hallmark Estrogen Response Early Geneset. e GSEA of 4559 genes
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signiﬁcantly downregulated in c as compared to the Hallmark Estrogen
Response Early Geneset. f MCF7 shKMT2C-R cells were treated with
DMSO, estradiol (E2), fulvestrant (Fulv.), AZD9496 (9496),
ARN1917 (1917), GDC927 (927), or RU58668 (58668) at indicated
doses. Proliferation assayed using the alamarBlue viability assay.
Values correspond to mean of 6 experimental replicates ± s.e.m. g
Percent of cases with mutations detected in patient samples (MSKCC
[50]) compared to those in TCGA Luminal A/B [10]. h Progression
free survival for ER+ breast cancer patients on single agent aromatase
inhibitor (AI)
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the interaction between ERα and FOXA1, a wellestablished pioneer factor essential for ERα activity.

KMT2C loss promotes hormone-independent ER+
breast cancer cell proliferation
Given the necessity for KMT2C in estrogen-driven growth,
we hypothesized that loss of KMT2C might facilitate a
hormone-independent growth state as might occur in the
context of hormone deprivation therapy. To assess the role
of KMT2C in this context, we took advantage of the ability
of MCF7 cells to grow in hormone-deprived conditions
after 3–4 months [24, 25]. Using similar conditions, we
observed that KMT2C-deﬁcient MCF7 cells displayed a
much more rapid time to growth with cells emerging in as
little as 2 weeks (Fig. 5a). Consistent with these differences,
control shRenilla cells continued to be growth arrested for
10–12 weeks beyond the time KMT2C knockdown cells
grew. By contrast, we found that this rapid outgrowth was
not observed in KMT2D knockdown cells (Fig. S14).
To investigate the basis of hormone-independent growth
in this context, we established a hormone-independent
MCF7 shKMT2C#2 cell line referred to as shKMT2C-R.
Next-generation DNA sequencing (IMPACT) of the
shKMT2C-R cells revealed no obvious acquired mutations
compared to parental cells that could explain the rapid
outgrowth in hormone-deprived media (Supplemental
Table 3).
We assayed for KMT2C mRNA levels in these resistant
cells and found that KMT2C levels remained suppressed
(Fig. S15A, B). We also performed H3K4me1 ChIPsequencing in these cells and found that the original
869 sites with reduced H3K4me1 continued to have reduced
levels of H3K4me1 (Fig. S15C, D). These data suggested
that the development of hormone-independent growth was
not merely through replacement of KMT2C activity upon
ERα enhancers by upregulating a different H3K4 methyltransferase (or suppressing the demethylase).
To interrogate whether there might be any unique
dependencies of these cells, we performed RNA sequencing
on the shKMT2C-R cells and compared their gene expression levels to that of parental shKMT2C#2 or shRenilla
MCF7 cells maintained in hormone-deprived media for
5 days (Fig. 5b, c). We found that genes downregulated in
shKMT2C-R cells were enriched for ERα target genes (Fig.
5d, e) and genes implicated in responses to growth factor
stimulation (Fig S16). We also examined genes upregulated
in the shKMT2C-R cells and found enrichment for genes
involved in metabolic pathways including fatty acid, inositol phosphate, glucose and amino acid metabolic pathways. However, no individual pathway appeared signiﬁcant
when we corrected for multiple hypothesis testing (data not
shown).
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As the gene expression data suggested an ongoing suppression of ERα target genes, we examined whether these
cells had become insensitive to the action of estrogen. We
tested the response of shKMT2C-R to estradiol (E2) and
found that the shKMT2C-R cells continued to respond to
E2 by increasing their proliferative rate (Fig. 5f). These data
suggest an ongoing responsiveness to the estrogen stimulated growth program, but a capability to proliferate in the
absence of ERα ligands. To determine if unliganded ERα
was still promoting growth in these cells, we examined their
response to ERα antagonism. Similar to E2 response,
shKMT2C-R cells were still dependent on ERα as they
were sensitive to inhibition by multiple selective ERα
degraders including fulvestrant, AZD9496, ARN1917,
SRN927, and RU58668 (Fig. 5f). These data together
suggested that the shKMT2C-R cells continue to be
responsive to an E2-driven growth program while unliganded ERα maintains essential roles under hormonedeprived conditions.
Given the dual effects of KMT2C in promoting
hormone-dependent tumor growth while suppressing
hormone-independent tumor growth, we examined the
clinical outcomes of patients with KMT2C loss. First, we
applied the gene expression signatures derived from
our shKMT2C cells (Fig. 3a) and our shKMT2C-R cells
(Fig. 5c, d) and compared them to gene expression data
from 1209 Luminal A and B breast cancer patients in the
METABRIC data set [26]. We were able to separate
the patients into three groups (high, mid, low) based on the
similarity of their gene expression data to the derived
gene expression signatures (Fig. S17) Those with a
high score had a gene expression proﬁle most similar to
that of KMT2C knockdown. We found that patients with
high scores were more likely to be have poorer overall
survival and be Luminal B in subtype than Luminal A
(Fig. S17).
Together these data suggest that whereas KMT2C loss
suppresses estrogen-driven tumor growth, it can also facilitate emergence of growth in hormone-depleted conditions.
In keeping, we noted that KMT2C mutation prevalence was
increased to over 30% among patients with metastatic,
hormone-refractory breast cancer compared to the ~9%
mutation frequency observed in primary, untreated Luminal
A/B TCGA breast cancer (Fig. 5g, S18). In support, we
went on to look at patients with metastatic breast cancer
who received single agent aromatase inhibitor and compared patients wildtype or mutant for KMT2C (truncation
mutations and deletions). We found that these patients with
unambiguously pathogenic KMT2C mutations had signiﬁcantly shorter progression-free survival (PFS) on hormone deprivation therapy than patients with wildtype
KMT2C, further supporting a role for KMT2C in hormone
resistance (Fig. 5h).
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Fig. 6 ERα is reprogrammed in shKMT2C-R cells. a Venn diagram
showing overlap between shKMT2C-R (in CSS, red) and shRenilla (in
full serum, purple) ERα binding sites. b HOMER motif analysis at the
10,512 novel ERα loci in shKMT2C-R. Full list in Fig. S17. c, e, g
IGV browser views for ERα in shRenilla and shKMT2C-R cells. Sites
of increased ERα binding outlined in orange. For CMYC, orange
outline encompasses a previously deﬁned AP-1 dependent ERα site
[34]. d, f, h qChIP analysis. IgG used as negative control. Values
correspond to mean percentage of input ± s.e.m. of triplicate qPCR
reactions of a single replicate. Data correspond to one representative
assay from a total of two independent assays

ERα is reprogrammed in the shKMT2C-R cells
Our ﬁndings for shKMT2C-R cells demonstrated that they
no longer required estrogen to support growth but maintained a dependence of ERα expression and reactivated ERα
gene expression programs. To examine the site of action of
ERα in this context, we performed ERα ChIP-sequencing of
these cells. Whereas we continued to identify many sites
seen in the shRenilla cells (n = 6598), we also identiﬁed
over 10,000 unique ERα binding sites (Fig. 6a). We performed motif analysis on these distinct sites and found
motifs of FOXA1 and AP-1,to be enriched (Fig. 6b, S19).
AP-1, in particular, has been previously shown to play a
major role in the hormone-independent outgrowth of ER+
breast cancer [27–33]. To test the relevance of AP-1 in
shKMT2C-R cells, we looked for ERα binding nearby to
target genes, IRX4 and MUC1, whose expression is known
to be regulated by AP-1 dependent ERα activity [20]. We
also assayed ERα binding at a known AP-1 dependent ERα
binding site upstream of c-MYC, a key driver of hormoneindependent growth [34]. We found signiﬁcant increases in
ERα binding downstream of IRX4 and MUC1 and at the
known AP-1-dependent ERα binding site in shKMT2C-R
cells as compared to control cells (Fig. 6c–h). These data
raise the possibility that AP-1 may, in part, be responsible
for reprogramming ERα under conditions of KMT2C loss.

Discussion
In this report, we utilize tumor genome sequencing analyses
to help uncover the H3K4 methyltransferase KMT2C as a
critical regulator of hormone-dependent ERα activity.
Although it is unlikely that KMT2C will prove to be the
only histone modiﬁer that regulates ERα function, the
ﬁndings in this report suggest it to be a key regulator of the
estrogen responsive phenotype with major implications for
hormone therapy of breast cancer.
The initial suggestion for a role for KMT2C in estrogen
dependence comes from its frequent mutation in primary
breast cancer. As most mutations appear to be deleterious,
we modeled KMT2C loss in breast cancer cell lines. We
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were surprised to ﬁnd that KMT2C loss led to a selective
proliferative defect in ER+-driven breast cancers. These
data were remarkable as no breast cancer model we tested
showed an obvious growth advantage from loss of KMT2C.
Given previous observations about the interaction between
H3K4me and nuclear receptor activities [16, 35–45], we
speculated that KMT2C might be an essential regulator of
ERα.
To examine the mechanisms of KMT2C-mediated regulation of ER+ breast cancer proliferation, we analyzed the
effect of its loss upon established gene expression signatures of ligand-activated ERα. KMT2C loss downregulated estrogen responsive gene expression. These
effects of KMT2C loss are notable in light of the previously
reported effects of KMT2C loss in other contexts, including
hematopoietic cells and stem cells, where its loss is predominantly associated with an increase in stem-like properties and chemotherapy resistance [20, 46, 47].
Speciﬁcally, previous work studying KMT2C in mouse
mammary stem cells suggested it to be tumor-promoting
[47], while our own work on human ER+ breast cancer
cells suggest KMT2C to be either tumor-suppressive or
tumor-promoting, depending on hormone availability. In
support of KMT2C acting as a tumor suppressor, KMT2C
loss has been shown to contribute to urothelial carcinomas
by forming a tumor suppressive complex with p53 [45].
This disparity in KMT2C function across multiple tissue
types points to the importance of cellular context in
understanding the functions of KMT2C. Whereas this gene
is among the most frequently mutated genes in all of cancer
[5], the dominant effects of its loss appear to be cell type
speciﬁc. Whether there are key shared functions of KMT2C
across different tissue types or malignancies remains to be
seen.
Early analyses of KMT2C biochemical activities and
KMT2C knockout cells pointed to an essential role for this
protein in generating the H3K4me1 mark associated more
frequently with enhancer sites [16]. In accordance, we
found H3K4me1, but not H3K4me3, to be lost speciﬁcally
at ERα enhancer sites in KMT2C knockdown cells. Moreover, ChIP-sequencing of H3K27ac demonstrated that
H3K4me1 loss coincided with sites of H3K27ac loss,
implying that these were sites of active ERα driven transcription. These data specify the mechanism of KMT2C
regulation of ERα function—through enabling transcriptional activity at ERα enhancer sites.
To understand the basis for how H3K4me1 might
inﬂuence ERα activity, we conducted ERα ChIPsequencing and found no signiﬁcant loss of ERα binding
despite the loss of expression of proximal ERα target genes.
How then does H3K4me1 inﬂuence ERα activity at these
enhancer sites? We note that in examining the region surrounding these bindings sites, it appears that sites predicted
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for ERα binding partners, such as FOXA1 and AP-1, are
prevalent. In addition, we observed that KMT2C loss led to
decreases in ERα interactions with multiple known binding
factors including MCM4, FOXA1 and TRPS1. Finally, as
independent proof of potential interactions of KMT2C and
FOXA1, Jozwik et al. recently uncovered a direct interaction between KMT2C and FOXA1. How FOXA1, AP-1,
and other speciﬁc factors ultimately coordinate KMT2Cdependent ERα activity will be an area for further
investigation.
Finally, we sought to understand the basis for tumors
selecting for loss of KMT2C. We note that not all KMT2C
mutations seen in breast cancer will recapitulate loss of
function but given that over 55% of KMT2C mutations are
truncation mutations and given the lack of a speciﬁc hotspot
mutation, our KMT2C knockdown cells provided a key
model to study the functional role of KMT2C in breast
cancer. We queried KMT2C mutation frequency at different
stages of breast cancer progression and observed a ~7%
mutation rate in primary breast cancer, a similar rate (~10%)
in metastatic breast cancer and a higher rate in hormoneindependent breast cancer (~30%). These data were in some
contrast to the proliferative defects we observed in ER+ cell
lines growing in hormone-containing media. We investigated whether there might be a selective advantage for its
loss in estrogen-depleted conditions. Here, we indeed
observed that KMT2C loss led to markedly accelerated
outgrowth of cells. These data were further corroborated by
examining how loss of KMT2C impacted patient survival.
Among these patients, KMT2C loss was correlated with
poorer survival outcomes and shortened PFS on aromatase
inhibitor therapy. In accordance, it was recently published
that low KMT2C expression was signiﬁcantly associated
with poor outcome [48]. Together, these data suggest that
KMT2C loss is likely to have complex effects on the clinical behaviors of breast cancers. We anticipate that under
some circumstances the loss of KMT2C will slow estrogendriven tumor growth and potentially be associated with
favorable outcomes. In other contexts, loss of KMT2C may
be permissive for tumors developing an estrogenindependent growth program, perhaps only in selected
genotypes where another growth program is sufﬁciently
active. Moreover, even in this context, our data would
suggest ERα may still be targetable as our shKMT2C-R
cells were still sensitive to SERD-mediated ERα antagonism. Indeed, our analyses of these shKMT2C-R cells suggest that KMT2C loss was permissive for large-scale
reprogramming of ERα such that it acquired thousands of
new binding loci. The function of these new binding sites is
not yet known, but the sensitivity of the cells to ERα
inhibitors suggest there may be key oncogenic functions
gained. It will thus be imperative to further understand the
growth requirements for different KMT2C-mutated tumors
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to better utilize this biomarker in selecting the types of
endocrine therapy most appropriate for this common clinical entity.

Methods
Plasmids
SGEP (pRRL) was a kind gift from C. Sawyers. psPAX2
and pVSVG vectors were kind gifts from P. Chi.

Cell Lines
All cell lines were maintained at 37 °C and 5% CO2 in a
humidiﬁed atmosphere. SKBR3, BT-474, Cama-1, T47D,
MCF10A HCC1954 and MDA-MB-231 MDA-MB-468
and HCC1806 cell lines were obtained from the American
Type Culture Collection, and MCF7 Tet-On cells were
obtained from Clontech. HEK293CT cells were a kind gift
from P. Chi. SK-BR-3, Cama-1, HCC1954 and MDA-MB468 and MCF7 cells were grown in DMEM-F12, T47D and
HCC1806 and MDA-MB-231 cells were grown in RPMI,
and HEK293CT cells were grown in DMEM, supplemented
with 10% heat-inactivated FBS, 100 µg/ml penicillin,
100 mg/ml streptomycin and 4 mM glutamine. MCF10A
cells were grown in DMEM-F12 supplemented with 5%
heat-inactivated horse serum, 100 µg/mL penicillin, 100 mg/
mL streptomycin, 4 mM glutamine, 20ng/mL EGF, 500 µg/
mL Hydrocortisone, 100ng/mL Cholera Toxin, and 10 µg/
mL Insulin. All cell lines tested negative for mycoplasma.
No cell line used is in the database of commonly misidentiﬁed cell lines. MCF-7, SKBR3 and MDA-MB-231
were authenticated by STR proﬁling. Cama-1, and T47D
and MCF10A, MDA-MB-468, HCC-1806, HCC-1954
were authenticated by next-generation (IMPACT)
sequencing.

Clinical samples (MSKCC set)
We previously described use of a 410-gene targeted
capture-based sequencing platform (MSK-IMPACT [49]) to
analyze 39 tumors with either recurrence of disease after
receiving adjuvant therapy or World Health Organizationdeﬁned progression of metastatic disease on therapy for
genomic alterations [50]. Informed consent was received
from all patients.

Sequencing breast cancer cell lines for the presence
of KMT2C alterations
MCF7, T47D, Cama-1, SKBR3, BT-474, MCF10A, MDAMB-468, HCC-1954, HCC-1806 and MDA-MB-231 cells
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were sequenced using the next-generation sequencing
(IMPACT) assay as previously described [49].

usual. Selection with 5–7 µg/ml puromycin was initiated
48 h after infection.

Generation of MCF7 KMT2C-HA by CRISPR/Cas9

Proliferation assays

The following guide RNA sequence targeting KMT2C exon
60 was selected using the Optimized CRISPR Design tool
(http://crispr.mit.edu
[51]):
AGCCGCCCGCTGAGCTAGCA.
DNA oligonucleotides were purchased from IDT and
cloned into px458-GFP vector [52]. For homologous
recombination, we purchased a custom IDT Ultramer
200 bp repair template with the HA sequence (TACCCATACGATGTTCCAGATTACGCT) directly upstream the
KMT2C stop codon. This 200 bp fragment contained two
silent mutations, one to remove the PAM site (TCC > TTC)
and another to introduce a HincII restriction enzyme
(GTGAAC > GTTAAC) site upstream of the HA tag. The
200 bp fragment also contained 87 bps of homology to
KMT2C exon 60 upstream of the HA tag and 83 bp of
homology to the KMT2C 3′UTR downstream of the stop
codon. 12ug of the targeting construct and 240 nM repair
template were nucleofected into MCF7 cells using the
Lonza Nucleofector V kit and Program P020 on the
Nucleofector device. Nucleofected cells were single cell
sorted based on GFP positivity 48 h following nucleofection. Clones were screened for the presence of successful
HA insertion by KMT2C exon 60 PCR and subsequent
restriction enzyme digest with HincII. Positive clones show
two digested products while negative clones only had a
single undigested band. A single positive clone, called
KMT2C-HA, containing the HA coding sequencing
downstream KMT2C was selected to carry out further studies. As a control, we used one of the negative clones from
the screening process, called KMT2C crispr control.

About 500–1000 cells in 200 µL of media were seeded per
well of a 96-well plate with six replicates per sample. If
necessary, cells were treated the following day, (Day 0). On
days when the plates were measured, 25 µL of Resazurin
(R&D Systems AR002) was added per well followed by 4 h
incubation at 37 °C. Plates were then read using a SpectraMax M5 (Molecular Devices) and results were analyzed
with Softmax Pro 6.2.2 software with an Endpoint Readtype
(Excitation: 560 nM, Emission: 590 nM). Results were
normalized to blank media with no cells.
For long-term estrogen deprived proliferation assay (Fig.
2f), 5000 cells were seeded in 200 µL of charcoal stripped
media. Media was replenished twice a week during the
course of the proliferation assay.

Lentiviral Infections
We plated HEK293CT packaging cells at 2.5 × 107 cells/
tissue culture dish (10 cm in diameter) and transfected them
with 2.25 µg of the SGEP lentiviral vector (encoding
shRenilla, shKMT2C #1 or shKMT2C #2), 2.25 µg of
psPAX2 and 0.5 µg of pVSVG with X-tremeGENE HP
(Roche) according to the manufacturer’s protocol. Conditioned medium containing recombinant lentivirus was collected and ﬁltered through non-pyrogenic ﬁlters with a pore
size of 0.45 µm (Millipore). Samples of these supernatants
were applied immediately to target cells, which had been
plated 18 h before infection at a density of 3 × 106 cells/
tissue culture dish (10 cm in diameter). Polybrene (Sigma)
was added to a ﬁnal concentration of 8 µg/ml, and supernatants were incubated with cells for 12 h. After infection,
cells were placed in fresh growth medium and cultured as

Immunoblotting
Cells were washed once with cold PBS and scraped off the
plate with a rubber policeman. The cell suspension was brieﬂy
centrifuged to pellet cells, PBS was removed, and the cell
pellet was stored at −80 °C until lysis. For cell lysis, pellets
were resuspended in a non-denaturing lysis buffer (Cell Signaling Technology) supplemented with protease and phosphatase inhibitors (Pierce) and were sonicated brieﬂy for 30 s.
Lysates were cleared by centrifugation at 14,000g for 10 min,
and protein concentration was determined using the BCA kit
(Pierce), which measures the reduction of Cu2+ to Cu1+ by
protein in an alkaline medium. For each sample, 25 µg of
protein lysate was loaded onto 4–12% SDS-PAGE minigels
(Invitrogen) for electrophoresis and immunoblotting against
H3K4me1 (Cell Signaling 5326), H3K4m3 (Cell Signaling
9727), Histone H3 (Cell Signaling 9715), ERα (Santa Cruz
7207), pERα S118 (Signalway Antibody 11072), pERα S167
(Cell Signaling 5587), pERα S104/106 (Cell Signaling 2517),
PR (Cell Signaling 8757), β-actin (Cell Signaling 4970).

Quantitative RT-PCR
RNA was extracted from cells 48 h after transfection or
from the mammary glands of 12-week old virgin females
using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s protocol. cDNA was synthesized with 1 µg
of RNA from each sample using the qScript cDNA
SuperMix (Quanta Biosciences) according to the manufacturer’s protocol. Synthesized cDNA was diluted with one
volume of DEPC-treated water, and 2 µl of the mixture was
added to TaqMan PCR Master Mix (Applied Biosystems)
along with primers. Relative quantiﬁcation for each mRNA
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was performed using the comparative CT method with a ViiA
7 Real-Time PCR system (Applied Biosystems)32. Samples
were run in triplicate, and mRNA levels were normalized to
those of RPLP0 or Gapdh for each reaction. TaqMan primers
were all purchased from Applied Biosystems. Catalog numbers are as follows: AGR3 (Hs00411286_m1), BANK1
(Hs01009378_m1), CA2 (Hs01070108_m1), CACNA1G
(Hs00367969_m1), CAV1 (Hs00971716_m1), CD44
(Hs01075861_m1), CXCL12 (Hs03676656_mH), ESR1
(Hs00174860_m1), GDNF (Hs01931883_s1), IGFBP4
(Hs01057900_m1), KMT2A (Hs00610538_m1), KMT2B
(Hs00207065_m1), KMT2C (Hs01005521_m1), KMT2D
(Hs00231606_m1), KRT13 (Hs02558881_s1), PEG10
(Hs00248288_s1), PGR (Hs01556707_m1), RPLP0
(Hs99999902_m1), SERPINA1 (Hs00165475_m1), SOX5
(Hs00753050_s1), TFF3 (Hs00902278_m1), TMPRSS3
(Hs00917537_m1), Kmt2c (Mm01156942_m1), Pgr
(Mm00435628_m1), Gapdh (4331182).

Chromatin Immunoprecipitation
Complexes were puriﬁed using H3K4me1 (abcam 8895),
H3K27ac (abcam 4729), and ERα (sc-453) -speciﬁc antibodies and DNA was puriﬁed using the PCR Puriﬁcation
Kit (Qiagen). ChIP primers are as follows CA2 enhancer
forward: 5′-GCAATCCTGAGAAACTGCAA-3′, reverse:
5′-GCTCCTGGCCTCAAACTATC-3′, PGR enhancer forward: 5′- GAGGGCTGTTGAAACAAACA-3′, reverse: 5′TGCTGAGATCACACCTAGACAA-3′, AGR2 enhancer
forward: 5′-ACGAAGCCTGCTT CTGAAC-3′, reverse:
5′-GTTTACAAGACATCAAACAACATGA-3′.
IRX4
enhancer forward: 5′- AGGGATCACTCCAGACTCCT-3′,
reverse: 5′- CTGAGTGCCAGATGTGCTTC-3′. MUC1
enhancer forward: 5′- TCCTCGAGAAGAGCAACTCC-3′,
reverse: 5′- CCGAGAGATCCGCTGTTAGT-3′. CMYC
enhancer forward: 5′- AAGACTGCCTCCCGCTTTGT-3′,
reverse: 5′- TGCTGCTGCTGCTGGTAGAA-3′.

Immunohistochemistry
Tissue were ﬁxed in 10% neutral buffered formalin for 48 h,
were processed in xylene and ethanol, embedded in parafﬁn,
sectioned at 4 µm thickness, and stained with hematoxylin
and eosin or with an antibody against the PR (Santa Cruz sc538) and then detected with SignalStain Boost IHC Detection Reagent (Cell Signaling, 8114). Slides were examined
by a board-certiﬁed pathologist (S. Monette, MSKCC).

Rapid immunoprecipitation mass spectrometry of
endogenous proteins (RIME)
RIME was performed as previously described [21, 22].
Brieﬂy, MCF7 cells were grown in SILAC Protein
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Quantiﬁcation Kit DMEM:F12 (Thermo Fischer Scientiﬁc
88439) supplemented with dialyzed FBS (Life Technologies 88440) with either L-Lysine-2HCl (Thermo Scientiﬁc
88429) and L-Arginine-HCl (Thermo Scientiﬁc 88427) for
light-labeled media or L-Arginine-HCl 13C6 (Cambridge
Isotope Laboratories 13E-430) and L-Lysine-2HCl 13C6,
15N2 (Cambridge Isotope Laboratories 14F-832) for heavylabeled media. A total of 60 million cells total with 30
million light labeled shRenilla cells and 30 million heavy
labeled shKMT2C#2 cells was used for each replicate. Ten
micrograms of antibody against ERα (Santa Cruz sc-543)
were used for each replicate. There were three replicates
done in total.
Immunoprecipitated samples were washed as previously
described and digested overnight with trypsin, peptides
desalted using C18 zip tips, and then dried by vacuum
centrifugation. Each sample was reconstituted in 10 µL
0.1% (vol/vol) formic acid and 4 µL analyzed by microcapillary liquid chromatography with tandem mass spectrometry using the NanoAcquity (Waters) with a 100-μminner-diameter × 10-cm- length C18 column (1.7 um
BEH130, Waters) conﬁgured with a 180-μm × 2-cm trap
column coupled to a Q-Exactive Plus mass spectrometer
(Thermo Fisher Scientiﬁc). Peptides were eluted with a
linear gradient of 0–35% acetonitrile (0.1% formic acid) in
water (0.1% formic acid) over 150 mins with a ﬂow rate of
300 nL/min. The QE Plus was operated in automatic, datadependent MS/MS acquisition mode with one MS full scan
(380–1800 m/z) at 70,000 mass resolution and up to ten
concurrent MS/MS scans for the ten most intense peaks
selected from each survey scan. Survey scans were acquired
in proﬁle mode and MS/MS scans were acquired in centroid
mode at 17,500 resolution and isolation window of 1.5 amu
and normalized collision energy of 27. AGC was set to 1 ×
10 [6] for MS1 and 5 × 10 [4] and 100 ms IT for MS2.
Charge exclusion of unassigned and greater than 6 enabled
with dynamic exclusion of 15 s. All MS/MS samples were
analyzed using MaxQuant (Max Planck Institute of Biochemistry, Martinsried, Germany; version 1.5.3.3) at default
settings with a few modiﬁcations. The default was used for
ﬁrst search tolerance and main search tolerance: 20 and
4.5 ppm, respectively. Labels were set to Arg6 and Lys8.
MaxQuant was set up to search the reference human proteome database downloaded from Uniprot on September 6,
2016. Maxquant performed the search assuming trypsin
digestion with up to two missed cleavages. Peptide, Site,
and Protein FDR were all set to 1%. One unique peptide
was required for high-conﬁdence protein identiﬁcations and
a minimum ratio count of two peptides (one unique and one
razor) were required for SILAC ratio determination. The
following modiﬁcations were used as variable modiﬁcations
for identiﬁcations and included for protein quantiﬁcation:
oxidation of methionine, acetylation of the protein N-
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terminus, phosphorylation of serine, threonine and tyrosine
residues.

Sequencing
RNA was extracted from MCF7 cells stably expressing
shRenilla, shKMT2C #1 and shKMT2C #2 using the
RNeasy Mini kit (Qiagen) according to the manufacturer’s
protocol. RNA size, concentration and integrity were analyzed using Agilent 2100 Bioanalyzer. Libraries were
generated using Illumina’s TruSeq RNA sample Prep Kit
v2, following the maufacturer’s protocol. Sequencing was
done on the HiSeq2500 sequencer as 50-bp paired-read with
30–40 million reads per sample by the NYU Genome
Technology Center.
The raw data were analyzed using Basepair software
(http://www.basepairtech.com/) with pipelines including the
following steps: raw reads were aligned to the transcriptome
derived from UCSC genome assembly hg19 using STAR
[53] with default parameters. Read counts for each transcript were measured using featureCounts [54]. Differentially expressed genes were determined using DESeq2 [55]
and a cut-off of 0.05 on adjusted p-value (corrected for
multiple hypotheses testing) was used for creating lists and
heatmaps, unless otherwise stated.

Chromatin Immunoprecipitation followed by
sequencing
A total of 2 × 106 MCF7 cells stably expressing either
shRenilla, shKMT2C #1 or shKMT2C 2 were ﬁxed with
1% formaldehyde at room temperature, lysed and sonicated
leading to a DNA average size of 200 bp. 1ug of H3K4me1
(abcam 8895), H3K27ac (abcam 4729) and ERα (Santa
Cruz HC-20)-speciﬁc antibodies was added to the samples
and incubated overnight at 4 °C. The complexes were puriﬁed using ChIP grade protein-A/G magnetic beads
(Thermo Scientiﬁc QB210263) followed by elution from
the beads and reverse cross-linking. DNA was puriﬁed
using PCR puriﬁcation columns (QIAGEN). H3K4me1,
H3K4me3 and ERα ChIP-seq libraries were prepared using
5ng of DNA and KAPA Hyper Prep Kit for Illumina,
according to the manufacturer’s protocol. Libraries were
validated using the Agilent 2200 Tapestation and KAPA
library quantiﬁcation qPCR assay and sequenced on a
HiSeq2500 sequencer as 50-bp single-end reads by the
NYU Genome Technology Center.
The raw data were analyzed using Basepair software
(http://www.basepairtech.com/) with pipelines including the
following steps: The raw fastq data were trimmed using
trim_galore to remove low-quality ends from reads (quality
<15) and adapter sequences. The trimmed data was aligned
using Bowtie2 [56] to UCSC genome assembly hg19.
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Duplicate reads were removed using Picard and bigwig ﬁles
were created for visualization. Peaks were identiﬁed with
Macs1.4 [57] and transcription factor binding motifs were
detected with Homer. Motifs were identiﬁed as enriched
over 48,246 randomly selected background sequences with
matched %GC content. Peaks overlapping with Satellite
repeat regions were discarded and remaining ﬁltered peaks
were annotated using custom scripts based on UCSC Flat
data [58], where peaks between −2500 and 2500 bp of a
transcription start site were marked as Promoter, the overlapping gene body were marked as Genebody and the rest
were marked as Intergenic. For intergenic peaks, a gene was
considered a target if it was within 1 Mb of the peak.

Generation of conditional KMT2C knockout mice
Mice with the Kmt2c ﬂoxed (F) allele were generated by
Biocytogen (Worcester, MA) in a C57BL/6 background. ES
cells were veriﬁed using Southern blotting. F/F mice were
bred to transgenic mice mice expressing the Cre enzyme in
the mammary tissue under the control of the MMTV longterminal repeat (mice were a kind gift from S. Lowe). Cremediated excision of the Kmt2c gene was veriﬁed by genotyping PCR of DNA extracted from toe clips or mammary
fat pads. Genotyping for the MMTV-cre transgenes were
done using generic Cre primers, forward (oIMR1084): 5′GCGGTCTGGCAGTAAAAACTATC-3′,
reverse
(oIMR1085): 5′-GTGAAACAGCATTGCTGTCACTT-3′,
as well as internal positive controls, forward (oIMR7338):
5′-CTAGGCCACAGAATTGAAAGATCT-3,
reverse
(oIMR7339):
5′-GTAGGTGGAAATTCTAGCATCATCC-3′. KMT2C ﬂoxed allele was genotyped using A1
primers, forward: 5′-GCAGAATCAAGGAGCTGTCTG3′, reverse: 5′-TGCCTTGAGGTCAACGTACAATTG-3′.
Cre mediated excision of KMT2C exon 3 was veriﬁed by
the presence of a 3′LoxP band at 372 bp using the following
primers, forward: 5′-GGAGCTGTCTGTTCAAGTATTTAGC-3′, reverse: 5′-GTGTGCCTAGGTATCCACAGAG-3′. For the in vivo experiments, 12-week were used.
All mice were housed in the MSKCC animal facility.

METABRIC [26] patients and tumor samples
A total of 1209 Luminal A and B breast cancer patients with
Illumina HumanHT-12 V3 expression beadchip array and
complete clinical annotation from the METABRIC data set
were included in the analysis.

Scoring for shKMT2C signatures with ssGSEA in
primary METABRIC patients
ssGSEA [2] was used to compute a set of different scores
based on in vitro-derived shKMT2C expression signatures.
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For each sample independently, an ssGSEA score was
calculated after gene expression levels were rank normalized and ordered, using the empirical cumulative distribution functions of genes in the signature and the reaming
genes as previously described [1, 2, 7] using the bioconductor package GSVA [6]. Patients were stratiﬁed into
high, low and intermediate scorers using population quartiles for the numerical ssGSEA score.

Study Population, clinical annotation and
prospective sequencing for patients with aromatase
inhibition treatment
A total of 671 breast tumor specimens from 466 patients
with ER+/HER2− metastatic breast cancer who received
aromatase inhibitors in metastatic setting underwent prospective clinical genomic proﬁling between April 2014 and
March 2017. For each treatment line, the time of biopsy
collection for MSK-IMPACT testing was compared with
the treatment start and stop dates. We excluded samples that
were collected after the start of CDK4/6 inhibitor therapy
(n = 263 samples) and only included samples that were
collected prior of therapy initiation. For the patients with
multiple sequenced specimens we only included one pretreatment sample and selected the sample that was collected
within a shorter time interval prior to initiation of aromatase
inhibitor therapy. The ﬁnal cohort included 347 pretreatment samples from 347 patients.
For all 347 patients, tumor and patient-matched normal
DNA samples were extracted from either representative
formalin-ﬁxed parafﬁn embedded tumor biopsy samples or
mononuclear cells from peripheral blood. All specimens
underwent massively parallel next-generation sequencing in
a CLIA-certiﬁed FDA-approved laboratory using MSKIMPACT, a hybridization capture-based next-generation
sequencing assay, which analyzes all protein-coding exons
and selected intronic and regulatory regions of 341 to 468
cancer-associated genes, all as previously described [4, 21].
Somatic mutations, DNA copy number alterations, and
structural rearrangements were identiﬁed as previously
described [21] and all mutations were manually reviewed.
The oncogenic KMT2C alterations were assessed using the
latest versions of the OncoKB [5] [www.oncokb.org] and
cancer hotspots [6] [www.cancerhotspots.org] knowledge
bases and only alterations that are considered “oncogenic”
or “likley oncogenic” were included in the analysis.

Generation of MCF7 KMT2C CRISPR by CRISPR/
Cas9nickase
The following guide RNA sequences targeting KMT2C
exon 6 were selected using the Optimized CRISPR Design
tool
(http://crispr.mit.edu
[51]):
gRNA1
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CTAGTGACCACTCCA
CACAACGG,
gRNA2
AGAACCATTGTTAGTGAACGTGG.
DNA oligonucleotides were purchased from IDT and
cloned into pX335-GFP vector [52] to generate targeting
constructs that were subsequently co-transfected in an
equimolar ratio into MCF7 cells using Lipofectamine HP
(Thermo Fischer Scientiﬁc). Seventy-two hours after
transfection, cells were sorted using a MoFlo cell sorter
(Beckman Coulter) for cells expressing Cas9 nickase (GFPpositive cells) and left to recover for 1 week before sorting
for single cells and allowing colonies to form. Indels within
the KMT2C exon 6 were detected using the Surveyor
Mutation Detection kit (IDT) and conﬁrmed by subcloning
and sequencing of KMT2C exon 6. One clone showing
knockout of all 2/3 KMT2C alleles was used for subsequent
analysis.

Statistics
Patient data was collected retrospectively; therefore, we
did not predetermine a sample size. Sample size estimates
for animal studies were determined based on previous
reports using similar sample sizes [59]. Samples were
placed into their experimental groups according to their
type, and so randomization was not used. Investigators
were not blinded to the experimental groups. Only female
mice were considered as predetermined by the fact that
we were interested in phenotypic effects to the mammary
gland. qPCR data and qChIP were obtained from independent technical replicates (n values indicated in the
corresponding ﬁgure legends). Normal distribution and
equal variance was seen in the majority of data and, so,
we assumed normality and equal variance for all samples.
On this basis, we used the Student’s t-test (two-tailed,
unpaired) to estimate statistical signiﬁcance. Analysis
was conducted using Prism v7.0c (GraphPad Software).
Survival for the METABRIC patient data was reported
using Kaplan–Meier curves, and signiﬁcance was estimated with the log-rank test. Statistical analysis for survival curves of patients with aromatase inhibitor
treatment used univariate Cox proportional hazard models to determine the association between oncogenic
KMT2C alterations and PFS with disease progression on
aromatase inhibitors or patient death. For patients with
multiple lines of therapy, only the ﬁrst treatment line
from that class that was started after the MSK-IMPACT
biopsy was included in the analysis. We tested the proportionality assumption of the Cox regression model
through time-dependency analysis of selected genetic
alterations (cox.zph function of the R package survival).
We rejected the null hypotheses with a two-sided α =
0.05. Statistical signiﬁcance was determined by log-rank
test stratiﬁed by the treatment.
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Study approval
All mice were treated with procedures approved by the
Institutional Animal Care and Use Committee. Access to
the METABRIC [26] cohort was obtained with consent
from the MSKCC institutional review board for anonymized evaluation of genomic associations. Study involving patients treated with aromatase inhibitors was
approved by the Memorial Sloan Kettering Cancer Center
Institutional Review Board and all patients provided
written informed consent for tumor sequencing and
review of patient medical records for detailed demographic, pathologic, and treatment information
(NCT01775072). Detailed treatment history data were
obtained for each patient and included all lines of systemic therapy from time of diagnosis of invasive carcinoma to the study data lock in May 2017. The exact
regimen as well as the dates of start and stop of therapy
were recorded for each treatment line.

Data deposition
Our ChIP sequencing and RNA sequencing data has been
deposited in NCBI GEO
Accession number: GSE100328.
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